ClinicalTrials.gg
RecruitingNCT05456321Updated Jan 20, 2026

CIFASD 5 tDCS and Cognitive Training

An interventional study of Active tDCS and Cognitive Training in Fetal Alcohol Spectrum Disorders, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States — 10 open to participants now, 11 under way, none of them phase 3. Fetal Alcohol Spectrum Disorders · United States.

Planned enrollment
19th of 34
70 · median 85
Started
2022
with 2 others
No phase
22 of 37
9 open now
Primary completion
2027-05
later than 6 of 10 live
Registered
26th of 37
by date
Lead sponsor
4 of 37
University of Minnesota

Among the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2022, is one of 22 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 26th registered.

Fetal Alcohol Spectrum Disorders

65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.

Browse Fetal Alcohol Spectrum Disorders studies →

Open to participants now

10 of the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Fetal Alcohol Spectrum Disorders studies recruiting now, 4 (33%) set no upper age limit and 8 (67%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a randomized placebo-controlled trial of cognitive training with transcranial direct current stimulation (tDCS) for children and adolescents (ages 8 - 17 years) with prenatal alcohol exposure (PAE).

Read the detailed description

Prenatal alcohol exposure (PAE) has profound detrimental effects on brain development and, as a result, has permanent consequences for cognition, learning, and behavior. Individuals with Fetal Alcohol Spectrum Disorders (FASD) commonly have a range of neurocognitive impairments that directly lead to practical problems with learning, attention, working memory, task planning/execution, and decision making, among other areas of functioning. Despite the profound public health burden posed by FASD, there have been very few treatment studies in this population. This study will examine the effects of a cognitive remediation training augmented with transcranial direct current stimulation (tDCS) in children and adolescents with PAE. The study involves a baseline visit with cognitive testing, 5 sessions of tDCS (including the baseline visit) with active and sham arms, a 6th visit for cognitive testing.

03

Conditions studied

  • Fetal Alcohol Spectrum Disorders
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented heavy prenatal alcohol exposure (self-report, social service records, or adoption records) and meeting criteria for an associated FASD diagnosis (FAS, partial FAS, or ARND).
  • An available parent or legal guardian capable of giving

Exclusion criteria

Exclusion Criteria:

  • Substance abuse in the participant
  • Neurological condition or other developmental disorder
  • Serious psychiatric disorder known to affect brain functioning and cognitive performance Birthweight \< 1500 grams
  • MRI
  • tDCS contraindication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Cognitive Training and Active tDCS

    5 sessions of computerized executive functioning training - plus active tDCS (also 5 sessions).

    Device: Active tDCS · Behavioral: Cognitive Training

  • Sham comparator
    Cognitive Training and Sham tDCS

    5 sessions of computerized executive functioning training - plus sham tDCS (also 5 sessions).

    Behavioral: Cognitive Training · Device: Sham tDCS

Interventions

  • DeviceActive tDCS

    Active Transcranial Direct Current Stimulation (tDCS)

  • BehavioralCognitive Training

    Computerized Cognitive Training

  • DeviceSham tDCS

    Sham Transcranial Direct Current Stimulation (tDCS)

06

What researchers measure

Primary outcomes

  1. Change in Continuous Performance Test performance

    Change in Continuous Performance Test performance

    Time frame: After each study visit (approx. bi-weekly) for the duration of the study (10 visits, approx. 5 weeks)

  2. Change in Delis-Kaplan Executive Function System -Trail Making performance

    Change in Delis-Kaplan Executive Function System - Trail Making performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

  3. Change in Delis-Kaplan Executive Function System Color Word Interference performance

    Change in Delis-Kaplan Executive Function System - Color Word Interference performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

  4. Change in Wechsler Digit Span performance

    Change in Wechsler Intelligence Scale for Children or Wechsler Adult Intelligence Digit Span performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

  5. Change in Wechsler Picture Span performance

    Change in Wechsler Intelligence Scale for Children or Wechsler Adult Intelligence Scale Picture Span performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

Secondary outcomes

  1. Change in Oral Word Reading Fluency performance

    Change in Oral Word Reading Fluency performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

  2. Change in Math Fluency performance

    Change in Mathematics Fluency performance

    Time frame: Visit 1 and Visit 5 (approx. 3 weeks apart)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is no plan to share IPD with other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for May 2027, 54 months after the start.

Of 28 interventional studies with no phase under Fetal Alcohol Spectrum Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2022
First posted
Jul 13, 2022
StartActual
Nov 10, 2022
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05456321
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Nov 10, 2022
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Jeffrey Wozniak, PhD
Contact
jwozniak@umn.edu
1-612-598-0041
Jeffrey R Wozniak, Ph.D.
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion